The c-fms proto-oncogene encodes the receptor for a hematopoietic growth factor, CSF-1. While the importance of c-fms and its ligand CSF-1 to hematopoietic malignancies is well recognized, we believe that activation of the c-fms proto-oncogene by binding to CSF-1 is important to the biology of ovarian cancer, and may underlie some of our findings of its malignant phenotype. Although during macrophage activation, the active cytokine CSF-1 stimulates the secretion of urokinase-type plasminogen activator (uPA) important to macrophage motility and invasion, until now, no such association between CSF-1 and uPA has been described for ovarian cancer. Our initial studies suggest that CSF-1 plays an important role in the neoplastic progression of ovarian cancer; we show that CSF-1, through the induction of uPA activity, stimulates invasion of ovarian cancer cells through an extracellular matrix. Moreover studies of the role of uPA, its receptor, and its inhibitors in ascites of ovarian cancer patients suggests that uPA is an important protease in the biology of ovarian cancer. In this application, we will focus on (1) elucidation of the mechanism behind overexpression of CSF-1 in ovarian cancer cell lines. Our preliminary studies suggest that a labile regulatory protein is involved in CSF-1 mRNA decay in ovarian cancer cells, and that an instability determinant which is sensitive to the actions of protein synthesis inhibitors, may reside in the AU-rich exon-10 of the 3' untranslated region of the CSF-1 transcript. We will determine the importance of the 3' AU-rich region of the CSF-1 transcript to its overexpression, to CSF-1 mRNA stability, and to RNA-protein binding. We plan to determine if proteins which may bind to the 3' end of CSF-1 mRNA may also bind to the 3' AU-rich region of the uPA transcript, and have identity with those that have been implicated in c-myc mRNA destabilization. We will then pursue (2) study of the effect of CSF-1 on factors important to uPA mediated plasminogen activation in ovarian cancer. Lastly, we plan to (3) define the clinical correlates of expression of CSF-1 and of uPA, its receptor, and its inhibitors, in the primary and metastatic tumor of ovarian cancer patients, in order to assess the importance of CSF-1/uPA to neoplastic progression. If the results of our studies suggest that the same trans-acting factor is responsible for regulation of CSF-1, uPA, c-myc and/or other transcripts that contain a 3' AU-rich element, then these findings would significantly impact on our understanding of the biology of ovarian and other cancers, and could lead to the development of new therapeutics. If the gene for the common trans-acting factor could be identified in the future, then development of gene-directed therapy using transduction of genes encoding high levels of the common destabilizing protein could be envisioned.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA060665-05
Application #
2895048
Study Section
Pathology B Study Section (PTHB)
Program Officer
Mohla, Suresh
Project Start
1995-04-15
Project End
2002-03-31
Budget Start
1999-04-01
Budget End
2002-03-31
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Yale University
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Woo, Ho-Hyung; Baker, Terri; Laszlo, Csaba et al. (2013) Nucleolin mediates microRNA-directed CSF-1 mRNA deadenylation but increases translation of CSF-1 mRNA. Mol Cell Proteomics 12:1661-77
Woo, Ho-Hyung; László, Csaba F; Greco, Stephen et al. (2012) Regulation of colony stimulating factor-1 expression and ovarian cancer cell behavior in vitro by miR-128 and miR-152. Mol Cancer 11:58
Chambers, Setsuko K (2009) Role of CSF-1 in progression of epithelial ovarian cancer. Future Oncol 5:1429-40
Zhou, Yi; Yi, Xiaofang; Stoffer, Jha'nae B et al. (2008) The multifunctional protein glyceraldehyde-3-phosphate dehydrogenase is both regulated and controls colony-stimulating factor-1 messenger RNA stability in ovarian cancer. Mol Cancer Res 6:1375-84
Toy, Eugene P; Bonafe, Nathalie; Savlu, Asim et al. (2005) Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis. Clin Exp Metastasis 22:1-9
Cracchiolo, Bernadette M; Hanauske-Abel, Hartmut M; Schwartz, Peter E et al. (2002) Procollagen-derived biomarkers in malignant ascites of ovarian cancer. Independent prognosticators for progression-free interval and survival. Gynecol Oncol 87:24-33